Parnax Lab Ltd
PARNAXLABParnax Lab Ltd
PARNAXLAB
Price Chart
Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
AvgCan be considered moderately valued vs the market
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
GoodThe stock is underpriced and is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 10.52 | 1.65 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 43.36 | 4.98 | 0.72% |
Forecast & Ratings
Detailed ForecastPrice
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Parnax Lab is principally engaged in the business activities of manufacturing and export of pharmaceutical formulations
Peers
Compare with peersSun Pharmaceutical Industries Ltd
Cipla Ltd
Dr Reddy's Laboratories Ltd
Mankind Pharma Ltd
Torrent Pharmaceuticals Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
Hmm, looks like data is unavailable here. Please come back after some timeRevenue Forecast
Hmm, looks like data is unavailable here. Please come back after some timeEarnings Per Share Forecast
Hmm, looks like data is unavailable here. Please come back after some timeIncome
Balance Sheet
Cash Flow
Income Statement
| Financial Year | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 103.56 | 71.92 | 95.18 | 106.69 | 110.89 | 95.97 | 90.27 | 163.36 | 168.38 | 179.91 | ||||||||||
Raw Materials | 64.80 | 37.10 | 58.02 | 62.23 | 59.93 | 54.43 | 48.49 | 101.47 | 101.31 | 155.20 | ||||||||||
| Power & Fuel Cost | 2.45 | 2.11 | 3.27 | 2.99 | 3.13 | 4.12 | 4.29 | 5.24 | 5.37 | |||||||||||
| Employee Cost | 7.72 | 7.46 | 9.22 | 11.68 | 13.06 | 14.08 | 13.68 | 17.43 | 20.05 | |||||||||||
| Selling & Administrative Expenses | 4.86 | 4.32 | 4.49 | 8.09 | 12.36 | 6.74 | 4.86 | 6.75 | 7.66 | |||||||||||
| Operating & Other expenses | 10.90 | 10.26 | 6.79 | 10.61 | 10.08 | 9.51 | 8.80 | 9.11 | 10.23 | |||||||||||
EBITDA | 12.83 | 10.67 | 13.39 | 11.09 | 12.33 | 7.09 | 10.15 | 23.36 | 23.76 | 24.71 | ||||||||||
| Depreciation/Amortization | 2.99 | 2.90 | 3.75 | 3.74 | 3.82 | 4.46 | 5.16 | 5.87 | 6.53 | 6.67 | ||||||||||
| PBIT | 9.84 | 7.77 | 9.64 | 7.35 | 8.51 | 2.63 | 4.99 | 17.49 | 17.23 | 18.04 | ||||||||||
| Interest & Other Items | 4.40 | 4.29 | 4.92 | 4.32 | 3.89 | 4.60 | 5.08 | 5.23 | 4.95 | 5.07 | ||||||||||
| PBT | 5.44 | 3.48 | 4.72 | 3.03 | 4.62 | -1.97 | -0.09 | 12.26 | 12.28 | 12.97 | ||||||||||
| Taxes & Other Items | 1.19 | 0.97 | 1.03 | 1.97 | 1.32 | 0.95 | 0.28 | 4.03 | 3.66 | 3.19 | ||||||||||
| Net Income | 4.25 | 2.51 | 3.69 | 1.06 | 3.30 | -2.92 | -0.37 | 8.23 | 8.62 | 9.78 | ||||||||||
| EPS | 5.00 | 2.95 | 4.34 | 1.25 | 3.88 | -3.43 | -0.44 | 8.98 | 8.09 | 8.51 | ||||||||||
| DPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||||
| Payout ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Company Updates
Annual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFPeers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Parnax Lab Ltd | 11.94 | 1.65 | — |
| Sun Pharmaceutical Industries Ltd | 33.73 | 4.82 | 0.97% |
| Cipla Ltd | 34.36 | 4.06 | 0.71% |
| Dr Reddy's Laboratories Ltd | 20.97 | 4.06 | 0.70% |
Price Comparison
Compare PARNAXLAB with any stock or ETFShareholdings
Promoter Holdings Trend
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Total Retail Holding
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Dec 2022
Mar 2023
Jun 2023
Sep 2023
Shareholding History
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No Dividends
PARNAXLAB has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
Hmm, looks like data is unavailable here. Please come back after some timeNews & Opinions
Parnax Lab Consolidated March 2023 Net Sales at Rs 40.91 crore, down 14.62% Y-o-Y
4 months ago•Moneycontrol
Parnax Lab Consolidated December 2020 Net Sales At Rs 24.83 Crore, Down 2.48% Y-o-Y
2 years ago•Moneycontrol
Parnax Lab Standalone December 2020 Net Sales At Rs 0.68 Crore, Down 68.2% Y-o-Y
2 years ago•Moneycontrol
Higher than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 9.56%, vs industry avg of 8.45%
Constant Market Share
Over the last 5 years, market share stayed at 0.05%
Higher than Industry Net Income
Over the last 5 years, net income has grown at a yearly rate of 52.07%, vs industry avg of 9.82%